HIV-1 Envelope (ENV) GP160 Trimer Protein Complex SPIKE as a Recombinant Macromolecular Assembly Vaccine Component Candidate: Current Opinion

Author(s):  
Christina Nilofer ◽  
Arumugam Mohanapriya ◽  
Pandjassarame Kangueane
1999 ◽  
Vol 19 (7) ◽  
pp. 4592-4599 ◽  
Author(s):  
Paul D. Bieniasz ◽  
Therese A. Grdina ◽  
Hal P. Bogerd ◽  
Bryan R. Cullen

ABSTRACT The human immunodeficiency virus type 1 (HIV-1) Tat protein (hTat) activates transcription initiated at the viral long terminal repeat (LTR) promoter by a unique mechanism requiring recruitment of the human cyclin T1 (hCycT1) cofactor to the viral TAR RNA target element. While activation of equine infectious anemia virus (EIAV) gene expression by the EIAV Tat (eTat) protein appears similar in that the target element is a promoter proximal RNA, eTat shows little sequence homology to hTat, does not activate the HIV-1 LTR, and is not active in human cells that effectively support hTat function. To address whether eTat and hTat utilize similar or distinct mechanisms of action, we have cloned the equine homolog of hCycT1 (eCycT1) and examined whether it is required to mediate eTat function. Here, we report that expression of eCycT1 in human cells fully rescues eTat function and that eCycT1 and eTat form a protein complex that specifically binds to the EIAV, but not the HIV-1, TAR element. While hCycT1 is also shown to interact with eTat, the lack of eTat function in human cells is explained by the failure of the resultant protein complex to bind to EIAV TAR. Critical sequences in eCycT1 required to support eTat function are located very close to the amino terminus, i.e., distal to the HIV-1 Tat-TAR interaction motif previously identified in the hCycT1 protein. Together, these data provide a molecular explanation for the species tropism displayed by eTat and demonstrate that highly divergent lentiviral Tat proteins activate transcription from their cognate LTR promoters by essentially identical mechanisms.


Retrovirology ◽  
2021 ◽  
Vol 18 (1) ◽  
Author(s):  
William M. McFadden ◽  
Alexa A. Snyder ◽  
Karen A. Kirby ◽  
Philip R. Tedbury ◽  
Monika Raj ◽  
...  

AbstractThe capsid core of HIV-1 is a large macromolecular assembly that surrounds the viral genome and is an essential component of the infectious virus. In addition to its multiple roles throughout the viral life cycle, the capsid interacts with multiple host factors. Owing to its indispensable nature, the HIV-1 capsid has been the target of numerous antiretrovirals, though most capsid-targeting molecules have not had clinical success until recently. Lenacapavir, a long-acting drug that targets the HIV-1 capsid, is currently undergoing phase 2/3 clinical trials, making it the most successful capsid inhibitor to-date. In this review, we detail the role of the HIV-1 capsid protein in the virus life cycle, categorize antiviral compounds based on their targeting of five sites within the HIV-1 capsid, and discuss their molecular interactions and mechanisms of action. The diverse range of inhibition mechanisms provides insight into possible new strategies for designing novel HIV-1 drugs and furthers our understanding of HIV-1 biology. Graphical Abstract


1998 ◽  
Vol 17 (23) ◽  
pp. 7056-7065 ◽  
Author(s):  
Paul D. Bieniasz ◽  
Therese A. Grdina ◽  
Hal P. Bogerd ◽  
Bryan R. Cullen

2020 ◽  
Vol 34 (12) ◽  
pp. 16319-16332
Author(s):  
Silvia Torices ◽  
Samantha A. Roberts ◽  
Minseon Park ◽  
Arun Malhotra ◽  
Michal Toborek

FEBS Letters ◽  
1997 ◽  
Vol 401 (2-3) ◽  
pp. 197-201 ◽  
Author(s):  
H.Y.Lim Tung ◽  
Hughes De Rocquigny ◽  
Ling-Jun Zhao ◽  
Xavier Cayla ◽  
Bernard P Roques ◽  
...  

2010 ◽  
Vol 263 (2) ◽  
pp. 166-171 ◽  
Author(s):  
Siham Salmen ◽  
Melisa Colmenares ◽  
Darrel L. Peterson ◽  
Elbert Reyes ◽  
Jose D. Rosales ◽  
...  
Keyword(s):  
P22 Phox ◽  

2012 ◽  
Vol 86 (14) ◽  
pp. 7662-7676 ◽  
Author(s):  
L. Yang ◽  
Y. Song ◽  
X. Li ◽  
X. Huang ◽  
J. Liu ◽  
...  

eLife ◽  
2014 ◽  
Vol 3 ◽  
Author(s):  
Xiaofei Jia ◽  
Erin Weber ◽  
Andrey Tokarev ◽  
Mary Lewinski ◽  
Maryan Rizk ◽  
...  

BST2/tetherin, an antiviral restriction factor, inhibits the release of enveloped viruses from the cell surface. Human immunodeficiency virus-1 (HIV-1) antagonizes BST2 through viral protein u (Vpu), which downregulates BST2 from the cell surface. We report the crystal structure of a protein complex containing Vpu and BST2 cytoplasmic domains and the core of the clathrin adaptor protein complex 1 (AP1). This, together with our biochemical and functional validations, reveals how Vpu hijacks the AP1-dependent membrane trafficking pathways to mistraffick BST2. Vpu mimics a canonical acidic dileucine-sorting motif to bind AP1 in the cytosol, while simultaneously interacting with BST2 in the membrane. These interactions enable Vpu to build on an intrinsic interaction between BST2 and AP1, presumably causing the observed retention of BST2 in juxtanuclear endosomes and stimulating its degradation in lysosomes. The ability of Vpu to hijack AP-dependent trafficking pathways suggests a potential common theme for Vpu-mediated downregulation of host proteins.


Sign in / Sign up

Export Citation Format

Share Document